Sanofi taps power of Paris Olympic sponsorship to encourage employees to find their ‘potential’

Roughly a month after announcing plans to merge several units under Sumitomo Pharma America this July, the drugmaker is making cuts in Massachusetts.

Sumitomo Pharma America Holdings and Sumitomo Pharma Oncology have announced a combined 122 layoffs to take effect June 30, according to Massachusetts’ WARN system. Another Sumitomo unit, Sunovion Pharmaceuticals, will make 101 cuts.

Sumitomo announced in early April that it was combining Sunovion, Sumitomo Pharma Oncology, Sumitomo Pharma America Holdings, Sumitovant Biopharma, Myovant Sciences, Urovant Sciences and Enzyvant Therapeutics to form Sumitomo Pharma America. Sumitomo said at the time that the combined company would house a “diverse portfolio of commercialized products and robust pipeline of early- to late-stage assets” across the central nervous system, oncology, urology, women’s health, and cell and gene therapies.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 167,200+ biopharma pros reading Endpoints daily — and it’s free.

One health approach to tackling Acanthamoeba infections at UNGA79

The session “Harnessing the Power of Nature: A One Health Approach Against Acanthamoeba” will be one of the key events at UNGA79, focusing on the

August 23, 2024

FDA sets October adcomm to discuss full approval for Amgen’s Lumakras to treat second-line lung cancer

The FDA will convene its oncology advisory committee in October to discuss Lumakras, Amgen’s KRAS-inhibiting oral medication as a second-line treatment for KRAS G12C-mutated non-small

August 22, 2023

Pro-charter PAC pours nearly $1 million into single Colorado State Board of Education primary – The Cannabist

Related Articles Nearly $1 million — mostly from a group supporting charter schools — has poured into the Democratic primary for a seat on the

June 22, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.